Sonic Healthcare Ltd (ASX: SHL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Sonic Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Sonic Healthcare Ltd (ASX: SHL)
Latest News
Opinions
These stocks made my share portfolio a market-beater in 2024
Cheap Shares
5 beaten-up ASX shares being bought by insiders
Mergers & Acquisitions
2 ASX 200 shares announcing acquisitions today
Broker Notes
2 ASX 200 shares to buy that this fund manager is bullish about
Healthcare Shares
Overinvested in CSL? Here are two alternative ASX healthcare stocks
Healthcare Shares
This bombshell for ASX healthcare shares could hit 6 million Australians
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why Meteoric Resources, Resolute Mining, Sonic Healthcare, and TechnologyOne shares are roaring higher
Healthcare Shares
Why this $13 billion ASX 200 healthcare stock is surging today
Share Market News
5 things to watch on the ASX 200 on Tuesday
Opinions
2 ASX stocks on my naughty list this Christmas
Share Gainers
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
Sonic Healthcare historically makes two partially or fully franked dividend payments to shareholders each year.
-
Sonic Healthcare generally pays its shareholder dividends in March and September.
-
Yes, Sonic Healthcare offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on its ordinary shares.
-
Sonic Healthcare Ltd listed on the ASX on 30 April 1987.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
04 Sep 2024 | $0.6300 | 0.00% | Final | 19 Sep 2024 |
01 Mar 2024 | $0.4300 | 0.00% | Interim | 21 Mar 2024 |
06 Sep 2023 | $0.6200 | 100.00% | Final | 21 Sep 2023 |
07 Mar 2023 | $0.4200 | 100.00% | Interim | 22 Mar 2023 |
06 Sep 2022 | $0.6000 | 100.00% | Final | 21 Sep 2022 |
08 Mar 2022 | $0.4000 | 100.00% | Interim | 23 Mar 2022 |
07 Sep 2021 | $0.5500 | 65.00% | Final | 22 Sep 2021 |
09 Mar 2021 | $0.3600 | 30.00% | Interim | 24 Mar 2021 |
07 Sep 2020 | $0.5100 | 30.00% | Final | 22 Sep 2020 |
10 Mar 2020 | $0.3400 | 30.00% | Interim | 25 Mar 2020 |
10 Sep 2019 | $0.5100 | 30.00% | Final | 25 Sep 2019 |
08 Mar 2019 | $0.3300 | 20.00% | Interim | 26 Mar 2019 |
12 Sep 2018 | $0.4900 | 30.00% | Final | 27 Sep 2018 |
06 Mar 2018 | $0.3200 | 20.00% | Interim | 10 Apr 2018 |
08 Sep 2017 | $0.0000 | 0.00% | Final | 11 Oct 2017 |
07 Mar 2017 | $0.3100 | 20.00% | Interim | 11 Apr 2017 |
08 Sep 2016 | $0.4400 | 30.00% | Final | 27 Sep 2016 |
03 Mar 2016 | $0.3000 | 30.00% | Interim | 06 Apr 2016 |
05 Sep 2014 | $0.4000 | 55.00% | Final | 23 Sep 2014 |
03 Sep 2012 | $0.2923 | 53.88% | Final | 09 Oct 2012 |
04 Mar 2011 | $0.1881 | 35.62% | Interim | 24 Mar 2011 |
08 Sep 2010 | $0.2818 | 43.47% | Final | 28 Sep 2010 |
03 Mar 2010 | $0.1932 | 43.48% | Interim | 25 Mar 2010 |
08 Sep 2009 | $0.2818 | 43.47% | Final | 28 Sep 2009 |
05 Mar 2009 | $0.1936 | 68.18% | Interim | 26 Mar 2009 |
08 Sep 2008 | $0.3200 | 100.00% | Final | 09 Oct 2008 |
28 Feb 2006 | $0.1500 | 100.00% | Interim | 20 Mar 2006 |
31 Aug 2005 | $0.2300 | 100.00% | Final | 19 Sep 2005 |
26 Feb 2004 | $0.1000 | 100.00% | Interim | 17 Mar 2004 |
SHL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Sonic Healthcare Ltd
Sonic Healthcare Limited (ASX: SHL) is a global healthcare provider. It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland. It is the second-largest provider in Belgium and New Zealand and the third-largest in the United States.
While pathology contributes the vast majority of the company's revenue, Sonic Healthcare is also a major provider of diagnostic imaging in Australia and is the largest medical centre operator in the country.
The company typically earns the majority of its revenue from its European pathology segment, followed by its Australia-New Zealand pathology operations.
SHL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
24 Dec 2024 | $27.56 | $0.15 | 0.55% | 312,689 | $27.42 | $27.68 | $27.36 |
23 Dec 2024 | $27.41 | $0.24 | 0.88% | 561,166 | $27.48 | $27.55 | $27.25 |
20 Dec 2024 | $27.17 | $-0.33 | -1.20% | 2,122,041 | $27.44 | $27.60 | $27.04 |
19 Dec 2024 | $27.50 | $-0.42 | -1.50% | 1,260,886 | $27.48 | $27.65 | $27.30 |
18 Dec 2024 | $27.92 | $-0.14 | -0.50% | 1,089,050 | $28.15 | $28.19 | $27.79 |
17 Dec 2024 | $28.06 | $0.27 | 0.97% | 1,000,471 | $27.65 | $28.25 | $27.61 |
16 Dec 2024 | $27.79 | $-0.23 | -0.82% | 1,056,208 | $27.97 | $28.00 | $27.70 |
13 Dec 2024 | $28.02 | $-0.08 | -0.28% | 743,483 | $27.97 | $28.20 | $27.92 |
12 Dec 2024 | $28.10 | $-0.18 | -0.64% | 702,765 | $28.19 | $28.40 | $28.06 |
11 Dec 2024 | $28.28 | $-0.16 | -0.56% | 997,730 | $28.48 | $28.63 | $28.28 |
10 Dec 2024 | $28.44 | $-0.16 | -0.56% | 1,324,160 | $28.84 | $28.84 | $28.44 |
09 Dec 2024 | $28.60 | $0.03 | 0.11% | 853,768 | $28.65 | $28.93 | $27.76 |
06 Dec 2024 | $28.57 | $-0.26 | -0.90% | 1,110,470 | $28.48 | $28.75 | $28.29 |
05 Dec 2024 | $28.83 | $-0.04 | -0.14% | 1,102,511 | $28.97 | $29.35 | $28.83 |
04 Dec 2024 | $28.87 | $0.11 | 0.38% | 848,339 | $28.57 | $29.10 | $28.51 |
03 Dec 2024 | $28.76 | $-0.23 | -0.79% | 1,318,868 | $29.01 | $29.18 | $28.73 |
02 Dec 2024 | $28.99 | $0.42 | 1.47% | 886,760 | $28.70 | $29.06 | $28.52 |
29 Nov 2024 | $28.57 | $-0.02 | -0.07% | 782,890 | $28.54 | $28.68 | $28.35 |
28 Nov 2024 | $28.59 | $0.15 | 0.53% | 1,071,616 | $28.45 | $28.91 | $28.42 |
27 Nov 2024 | $28.44 | $-0.24 | -0.84% | 848,135 | $28.68 | $28.78 | $28.43 |
26 Nov 2024 | $28.68 | $0.72 | 2.58% | 819,867 | $28.00 | $28.85 | $27.96 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
11 Dec 2024 | Christine Bennett | Buy | 1,000 | $28,483 |
On-market trade.
|
10 Dec 2024 | Kathryn (Kate) Spargo | Buy | 1,500 | $42,765 |
On-market trade.
|
10 Dec 2024 | Mark Compton | Buy | 1,000 | $28,460 |
On-market trade.
|
09 Dec 2024 | Suzanne Crowe | Buy | 348 | $9,991 |
On-market trade.
|
19 Nov 2024 | Christopher Wilks | Issued | 142,746 | $3,995,460 |
Issue of options.
|
19 Nov 2024 | Christopher Wilks | Expiry | 181,147 | $5,070,304 |
Options expired.
|
19 Nov 2024 | Christopher Wilks | Issued | 27,570 | $771,684 |
Issue of securities. 75,994 Rights
|
19 Nov 2024 | Colin Goldschmidt | Expiry | 407,747 | $11,412,838 |
Options expired.
|
19 Nov 2024 | Colin Goldschmidt | Issued | 65,700 | $1,838,943 |
Issue of securities. 182,000 Rights
|
19 Nov 2024 | Colin Goldschmidt | Issued | 340,163 | $9,521,162 |
Issue of options.
|
27 Sep 2024 | Christopher Wilks | Expiry | 71,059 | $1,896,564 |
Options expired.
|
27 Sep 2024 | Christopher Wilks | Expiry | 11,264 | $300,636 |
As advised by the company. Forfeited
|
27 Sep 2024 | Colin Goldschmidt | Expiry | 186,467 | $4,976,804 |
Options expired.
|
27 Sep 2024 | Colin Goldschmidt | Expiry | 29,557 | $788,876 |
As advised by the company. forfeited, 116,300 Rights
|
23 Sep 2024 | Colin Goldschmidt | Transfer | 41,663 | $1,089,070 |
As advised by the company. legally transferred into Dr Goldschmidt's name.
|
23 Sep 2024 | Colin Goldschmidt | Transfer | 41,663 | $1,089,070 |
As advised by the company. legally transferred into Dr Goldschmidt's name.
|
23 Sep 2024 | Christopher Wilks | Transfer | 21,711 | $567,525 |
As advised by the company. legally transferred into Mr Wilks name.
|
23 Sep 2024 | Christopher Wilks | Transfer | 21,711 | $567,525 |
As advised by the company. legally transferred into Mr Wilks name.
|
29 May 2024 | Christine Bennett | Buy | 1,000 | $24,010 |
On-market trade.
|
23 May 2024 | Suzanne Crowe | Buy | 2,000 | $50,639 |
On-market trade.
|
23 May 2024 | Mark Compton | Buy | 1,000 | $25,350 |
On-market trade.
|
22 May 2024 | Katharine Giles | Buy | 500 | $12,357 |
On-market trade.
|
19 Apr 2024 | Christine Bennett | Transfer | 2,000 | $54,580 |
Off-market transfer.
|
19 Apr 2024 | Christine Bennett | Transfer | 2,000 | $54,580 |
Off-market transfer.
|
05 Mar 2024 | Christine Bennett | Buy | 1,100 | $31,373 |
On-market trade.
|
01 Mar 2024 | Christopher Wilks | Buy | 16,187 | $471,851 |
Conversion of securities.
|
01 Mar 2024 | Christopher Wilks | Exercise | 22,050 | $642,757 |
Conversion of securities. 59,688 Rights
|
01 Mar 2024 | Christopher Wilks | Buy | 5,863 | $170,906 |
Conversion of securities.
|
01 Mar 2024 | Colin Goldschmidt | Exercise | 52,695 | $1,536,059 |
Conversion of securities. 1,45,857 Rights
|
01 Mar 2024 | Colin Goldschmidt | Buy | 42,478 | $1,238,233 |
Conversion of securities.
|
01 Mar 2024 | Colin Goldschmidt | Buy | 10,217 | $297,825 |
Conversion of securities.
|
22 Feb 2024 | Katharine Giles | Buy | 250 | $7,222 |
On-market trade. 2,500 Prior holding
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Christopher David Wilks | Chief Financial OfficerFinance Director | Dec 1989 |
Mr Wilks has a background in chartered accounting and investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in a number of public companies and is currently a Non-executive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996.
|
Dr Colin Stephen Goldschmidt | Chief Executive OfficerManaging Director | Jan 1993 |
Dr Goldschmidt became CEO of Sonic has led Sonic's global expansion by committing the Company to a unique model of Medical Leadership, which incorporates operational and cultural attributes focussed on care for staff and quality service to doctors and patients. He is a member of Risk Management Committee and holds memberships with industry, medical and laboratory associations.
|
Mr Mark Raymond Compton | Non-Executive DirectorNon-Executive Chairman | Oct 2014 |
Mr Compton has senior executive experience in healthcare services. He is currently Adjunct Professor in Management (Healthcare Leadership) at Macquarie University (Macquarie Business School), Non-executive Director of The Hospitals Contribution Fund of Australia and Non-executive Chairman of not for-profit organisations St Luke's Care and the Order of St John (St John Ambulance). His previous experience includes Chief Executive Officer of each of St Luke's Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia. Prof. Compton has also held a number of non-executive director roles. He was also Chairman of the Woolcock Institute of Medical Research, Non-executive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia (having served as a volunteer for more than 45 years).
|
Mr Neville Mitchell | Non-Executive Director | Sep 2017 |
Mr Mitchell has international healthcare and finance experience. He was Chief Financial Officer and Company Secretary of ASX-listed Cochlear Limited (until March 2017), a medical device developer, manufacturer and seller of hearing devices. He was formerly a Non-executive Director of QBiotics Group Limited (from November 2017 to May 2023). He has also performed roles with a number of industry and government committees. Mr Mitchell is member of the Risk Management Committee.
|
Professor Suzanne Crowe | Non-Executive Director | Apr 2020 |
Professor Crowe was a Non-executive Director of St Vincent's Health Australia Ltd from January 2013 until October 2021. She retired from Burnet Institute as Associate Director in 2018 following a 30-year research career, having played a role in Burnet's development as a global research organisation. Professor Crowe retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She has served as a Member of the Prime Minister's Science Engineering and Innovation Council (India/China Working Group), as Head of the World Health Organization (WHO) Regional Reference Laboratory for HIV Resistance Testing and as an HIV advisor to WHO for 25 years. She was appointed a Fellow of the Australian Academy of Health and Medical Sciences in 2015. Professor Crowe is Chair of the Risk Management Committee.
|
Professor Christine Constance Bennett | Non-Executive Director | Sep 2022 |
Ms Bennett has over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. Professor Bennett is an experienced non-executive director in for profit and social enterprises and is currently a Non-executive Director of Convenor of the Champion of Change Health Group for gender equality. She is an advisor to the Digital Health Cooperative Research Centre and in 2024 completed a certificate on AI Ethics and Board Oversight. Her previous Board non-executive director roles include Telstra Health, HeartWare Limited, Symbion Health Limited and Chair of Sydney Children's Hospital Network. In December 2021, Professor Bennett retired from The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships and Dean, School of Medicine, Sydney for over ten years. Her prior experience has included being Group Executive and Chief Medical Officer for MBF and then Bupa Health and Care Services; CEO and later Chair of Research Australia; Managing Director of Total Health Enterprise Ltd; Partner in Health and Life Sciences for KPMG Australia; CEO of Westmead Hospital and Community Health Services; General Manager for the Royal Hospital for Women; and Head of Planning in NSW Health. Professor Bennett has a commitment to and involvement in medical professional issues, public policy and medical research. In 2008 she was appointed as Chair of the National Health and Hospitals Reform Commission producing a long-term blueprint for reform of health and aged care in Australia. Professor Bennett is a member of the Risk Management Committee.
|
Ms Kathryn (Kate) Dianne Spargo | Non-Executive Director | Jul 2010 |
Ms Spargo has gained business experience as a legal advisor, having worked in private practice and government, and as a director. Ms Spargo has been a director of both listed and unlisted companies over the last 20 years. Ms Spargo also holds non-executive director roles with CIMIC Group Limited, the Future Fuels Cooperative Research Centre and Geelong Football Club Limited. Ms Spargo was previously a Non-executive Director of Fletcher Building Limited, Xenith IP Group Limited and Adairs Limited (from May 2015 to 11 September 2024).
|
Dr Katharine Giles | Non-Executive Director | Sep 2022 |
Dr Giles, after initially practicing as a medical doctor, moved to commercial pursuits which combined science, medicine and health. Dr Giles is currently Managing Director and Chief Executive Officer of OncoRes Medical (since 2017), which is developing a novel imaging technology to improve cancer outcomes. Dr Giles is also a Venture Partner at Brandon Capital Partners (since 2012), a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specialising in seed-to-early-stage technology investment. Dr Giles has start-up experience in medical apps, diagnostics and fitness devices and has served on the boards of private health care related technology companies. She is a member of the Curtin University Commercialisation Advisory Board and currently serves on the board of the Australian Government's National Reconstruction Fund.
|
Mr Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer |
-
|
|
Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 161,840,103 | 33.69% |
J P Morgan Nominees Australia Pty Limited | 60,610,409 | 12.62% |
Citicorp Nominees Pty Limited | 42,296,322 | 8.80% |
Jardvan Pty Ltd | 15,109,474 | 3.15% |
BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 8,796,938 | 1.83% |
BNP Paribas Noms Pty Ltd | 6,701,631 | 1.39% |
BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 5,284,606 | 1.10% |
National Nominees Limited | 4,967,870 | 1.03% |
Argo Investments Limited | 3,726,053 | 0.78% |
Netwealth Investments Limited <Wrap Services A/C> | 3,565,479 | 0.74% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 3,461,262 | 0.72% |
Australian Foundation Investment Company Limited | 3,159,672 | 0.66% |
Washington H Soul Pattinson And Company Limited | 2,326,857 | 0.48% |
IOOF Investment Services Limited <Ips Superfund A/C> | 1,914,028 | 0.40% |
Gerhard Risch | 1,864,163 | 0.39% |
Blaise Mentha | 1,850,000 | 0.39% |
Polly Pty Ltd <A/C Patterson Family> | 1,817,416 | 0.38% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 1,713,397 | 0.36% |
Quintal Pty Ltd <Harken Family A/C> | 1,587,908 | 0.33% |
Netwealth Investments Limited <Super Services A/C> | 1,569,741 | 0.33% |